AgentFlare

Markets · Health Care · LLY · NYSE

Eli Lilly (LLY) at $1,252.00 after a 25.7% six-month gain and a 41.87 P/E

Eli Lilly shares trade at $1,252.00 after a 25.7% six-month gain, with a P/E of 41.87 against a tracked peer median of 29.40. Recent headlines cover a proposed shareholder share sale and pipeline developments.

Price$1,252.00+3.58%
1 month-0.88%
6 months+25.70%
Market cap$1.18T
P/E41.87
Net margin33.5%
LLY — 6-month daily close2026-04-14 → 2026-09-03 · AISA Financial API
LLY daily close: 04-14 $922.50 → 09-03 $1160; high $1280 (08-19), low $851.21 (04-29)$816.88$982.81$1149$131504-1406-2409-03
402 · Pay-per-Crawl$0.01

You're reading the full report — free for humans and search engines. The same content ships as a structured JSON dataset (normalized facts, sources and citation arrays, no HTML parsing) so AI agents can consume it directly — metered per fetch via the open HTTP 402 payment protocol.

⚡ Agents: fetch .data.json · $0.01 → agents: crawlerAutoPrice=true · verify at https://esa.aisa.one/api/v1/access/verify

What the company does

Eli Lilly and Co operates in the pharmaceuticals industry within the Health Care sector. The company is based in Indiana, U.S.A., and its shares trade on the NYSE under the ticker LLY. With a market capitalization of $1.18T, it is a large listed company in its sector. Reported profitability includes a gross margin of 83.4%, an operating margin of 42.2% and a net margin of 33.5%. The company also reports a debt-to-equity ratio of 1.62, which investors often weigh alongside its growth and pipeline.

Price action and valuation versus peers

Shares last traded at $1,252.00, up 3.58% on the day. Over roughly one month the stock is down 0.9%, while it is up 3.1% over roughly three months and up 25.7% over roughly six months. Its six-month high is $1,280.34, reached on 2026-08-19, and its low is $851.21, reached on 2026-04-29. Against tracked Health Care peers, the P/E of 41.87 compares with a peer median P/E of 29.40 across UNH and JNJ. The PEG ratio is 0.44, with P/S at 14.79, P/B at 34.77 and EV/EBITDA at 34.25. Latest year-over-year revenue grew 49.6% and earnings grew 93.6%.

What the recent headlines say

Stock Titan reported that shareholder Lilly Endowment has proposed a sale of 305,000 shares. GuruFocus said a GF Score of 96 signals strong outperformance potential for the stock. Benzinga published an article on how much an investor would have made owning the stock over the last 20 years. StocksToTrade linked the stock's move higher to a deepening obesity and diabetes pipeline. ETF Database covered a new peptide ETF from REX that looks beyond GLP-1 drugs. Moomoo also published a stock note on the company.

Fundamentals

P/E vs Health Care peersTracked peers in the same sector · ▶ this stock
price-to-earnings: ▶ LLY 41.9, JNJ 29.4, UNH 26.1▶ LLY41.9JNJ29.4UNH26.1
Margins & returnsLatest reported period
margins: Gross 83.4%, Operating 42.2%, Net 33.5%, ROE 78.8%Gross83.4%Operating42.2%Net33.5%ROE78.8%
Growth, year over yearLatest reported period
growth: Revenue +49.58%, Earnings +93.56%, Free cash flow +272.37%, EPS +94.88%Revenue+49.58%Earnings+93.56%Free cash flow+272.37%EPS+94.88%
Market cap$1.18TEnterprise value$1.22T
P/E41.87P/S14.79
P/B34.77EV/EBITDA34.25
PEG0.44EPS$29.89
Debt/equity1.62Current ratio1.35
FCF yield1.5%Payout ratio21.7%

Recent headlines

In the AgentFlare Newswire

What to watch

  • Proposed sale of 305,000 shares by shareholder Lilly Endowment
  • Progress of the obesity and diabetes pipeline
  • Performance of the new REX peptide ETF beyond GLP-1 drugs

FAQ

What does Eli Lilly do?

Eli Lilly and Co operates in the pharmaceuticals industry within the Health Care sector. It is based in Indiana, U.S.A., and trades on the NYSE under the ticker LLY, with a market capitalization of $1.18T.

How does Eli Lilly's valuation compare with peers?

Its P/E is 41.87, compared with a tracked Health Care peer median P/E of 29.40 across UNH and JNJ. Its PEG ratio is 0.44, P/S is 14.79 and EV/EBITDA is 34.25.

What does the proposed share sale headline mean?

Stock Titan reported that shareholder Lilly Endowment has proposed selling 305,000 shares. The headline describes a proposal only and does not indicate how or when any sale would occur.

How this page is made. Prices, fundamentals and headlines come from the AISA Financial API; peers are the other tracked stocks in the same sector. The profile is written by a language model from those numbers and headlines only — figures not in the data are removed. Nothing here is investment advice.

Sources & citations

  1. A 305,000-share sale is proposed by Eli Lilly (LLY) shareholder Lilly Endowment. - Stock Titan Stock Titan · 2026-10-15
  2. Eli Lilly and Co (LLY): GF Score of 96 Signals Strong Outperformance Potential - GuruFocus GuruFocus · 2026-10-15
  3. $Eli Lilly and Co (LLY.US)$ - Moomoo Moomoo · 2026-10-15
  4. Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 20 Years - Benzinga Benzinga · 2026-10-15
  5. LLY Stock Powers Higher As Obesity And Diabetes Pipeline Deepens - StocksToTrade StocksToTrade · 2026-10-14
  6. AISA Financial API
  7. Eli Lilly & Co SEC filings

Related